The global fight against antibiotic resistance is taking a significant leap forward — but here’s where it gets controversial: How effective will these new initiatives truly be? Recently, a remarkable announcement was made by a coalition of philanthropic organizations all dedicated to tackling one of the most urgent health crises of our time. They revealed a substantial grant of $60 million aimed specifically at pioneering research into novel antibiotics, targeting some of the most formidable bacterial adversaries that threaten public health today.
This collective effort involves prominent players such as the Gates Foundation, the Novo Nordisk Foundation, and Wellcome Trust. The funds, allocated through the initiative known as Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), will support scientific teams across 17 diverse nations—including countries like Ghana, South Africa, and Brazil. Launched at the beginning of 2025, Gr-ADI represents a strategic response to the persistent scarcity of new antibiotics capable of fighting gram-negative bacteria, a group notorious for their resilient outer membrane that makes them particularly challenging for drug developers.
And this is the part most people miss: over 500 research proposals flooded into Gr-ADI, signaling a global surge of interest and urgency. This initiative is pioneering because it fosters unprecedented levels of transparency and collaboration — research teams and funders openly share data, findings, and strategies, all working hand-in-hand to accelerate the discovery of highly needed antibiotics. Imagine a consortium where collective knowledge drives faster solutions; that’s a game-changer in the world of antimicrobial research.
According to Trevor Mundel, MD, PhD, who is President of Global Health at the Gates Foundation, antimicrobial resistance (AMR) is increasingly threatening our ability to treat even simple infections, risking millions of lives, especially in lower- and middle-income countries where healthcare resources can be limited. He emphasized that Gr-ADI aims to speed up discoveries that can quickly lead to new antibiotics, equipping nations with critical tools to safeguard public health now and well into the future.
But here’s an important question to consider: as we pour resources into novel antibiotics, how prepared are we to prevent the overuse and misuse of these life-saving drugs? Will these innovations be enough to curb the dangerous rise of resistant bacteria?
Switching gears, let's look at recent research related to influenza — specifically, antiviral treatments in children during the COVID-19 pandemic. A new study published in Pediatrics revealed a startling decline in antiviral use for hospitalized children with flu during the pandemic period. Before the pandemic, nearly half (48% to 57%) of these young patients received antivirals like oseltamivir, but that number tumbled to around 38% in 2021-2022 and about 46% in 2022-2023.
This decline is particularly troubling because antivirals play a crucial role in reducing symptom duration and preventing severe complications in children. Guidelines from the American Academy of Pediatrics recommend giving antivirals promptly to hospitalized children with suspected or confirmed influenza, especially if they are severely ill or at increased risk of complications, regardless of whether a lab test has confirmed the virus.
The study involved 1,560 children and found that those with underlying health issues, those vaccinated against flu, or those showing severe symptoms were more likely to receive antiviral medications. The drugs studied included oseltamivir, peramivir, baloxavir, and zanamivir—all vital tools in our influenza fight.
Alongside this, researchers noted an alarming decline in flu vaccinations among hospitalized children, falling from 47% before the pandemic to just 33% during the late pandemic period. Experts cited misinformation and growing mistrust in healthcare during COVID-19 as possible contributors, alongside a troubling belief among some parents and even healthcare providers that influenza in children is typically mild and self-limiting — despite evidence showing serious complications can and do occur, including hospitalizations and fatalities in otherwise healthy children.
These findings raise crucial questions: Are we underestimating the true severity of flu in children? And what can be done to reverse this downward trend in vaccination and treatment — especially when the stakes are so high?
Our underwriters
Support for the ASP initiative is generously provided through unrestricted financial backing, ensuring ongoing progress in these vital areas of health research.
